SYBOSS
Systems Biology of Stem Cells and Reprogramming
| Coordinatore | TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://syboss.eu/ |
| Totale costo | 13˙670˙200 € |
| EC contributo | 10˙530˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-two-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-06-01 - 2015-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
DE (DRESDEN) | coordinator | 4˙004˙403.50 |
| 2 | KOBENHAVNS UNIVERSITET | DK | participant | 1˙101˙335.20 |
| 3 |
INSTITUT CURIE
Organization address
address: 26, rue d'Ulm contact info |
FR (PARIS) | participant | 871˙600.00 |
| 4 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 860˙560.00 |
| 5 |
GENOME RESEARCH LIMITED
Organization address
address: THE GIBBS BUILDING, EUSTON ROAD 215 contact info |
UK (LONDON) | participant | 745˙280.00 |
| 6 |
DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
DK (KONGENS LYNGBY) | participant | 722˙480.00 |
| 7 |
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Organization address
address: Ingolstaedter Landstrasse 1 contact info |
DE (MUENCHEN) | participant | 542˙559.50 |
| 8 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 493˙440.00 |
| 9 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 434˙200.00 |
| 10 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 397˙625.30 |
| 11 |
KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
DE (KOELN) | participant | 356˙516.40 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Stem cells are central to emerging concepts in health, medicine and therapy. The realization that specific cell reservoirs retain multipotency for tissue establishment and replenishment has implications for both the emerging field of regenerative therapy and the long standing problems of cancer, ageing and degenerative diseases. Recently the prospects for regenerative therapy have been boosted by the breakthrough finding that somatic cells can be reprogrammed into pluripotent embryonic stem (ES) cells upon expression of ES cell transcription factors. This astonishing finding further emphasizes the need to understand stem cell biology. Most of the information acquired on stem cells so far is empirical. Recent progress in systematic and computational methodologies, including seminal contributions by the applicants, permits a new approach to stem cell biology. We can now describe the systems biology of stem cells. This proposal is based on the importance of stem cells in future medicine and the need to understand the fundamental mechanisms that regulate their potential to differentiate towards specific lineages. We aim to gather the information required to understand the regulomes of key stem cells, particularly the transition between embryonic (ES) and neural (NS) cells. NS cells can be readily reprogrammed back to ES cells. We will systematically gather proteomic, transcriptomic, regulomic, live cell and cell cycle data to understand the ES – NS axis comprehensively (in both directions). We will validate the regulatory data by functional interrogation using RNAi screens and tests, complemented by quantitative fluorescent read-outs. To broaden the fundamental and medical relevance of the insights, we will pursue selected studies on other stem cells (e.g. HSCs), and their differentiated products. Thereby we will acquire a broader grasp on stem cell issues and also significantly advance mammalian systems biology.'
Introduzione (Teaser)
Recently, regenerative therapy has been boosted by the breakthrough finding that normal body cells, somatic cells, can be reprogrammed into pluripotent embryonic stem (ES) cells.
Descrizione progetto (Article)
Stem cells are central to emerging concepts in health, medicine and therapy. Specific somatic cells retain the ability for tissue growth and repair. This has implications for both regenerative therapy and the long standing problems of cancer, ageing and degenerative diseases.
That somatic cells can be reprogrammed to behave like ES cells further emphasises the need to elucidate stem cell biology.
The EU-funded 'Systems biology of stem cells and reprogramming' (http://syboss.eu/ (SYBOSS)) project is dedicated to gathering data to build a systems biology understanding of stem cells. A key property of stem cells is their capacity to develop or differentiate into specific cell types that lose their multi-potency but acquire cell type-specific characteristics. So a skin cell has specifically skin cell characteristics.
SYBOSS is also applying a systems biology approach to study selected stagesbetween the multi-potent stem cell state and the final cell form .
Mouse embryonic stem cells (mESCs) maintain genome stability and physiological normality. They can develop into other cell types, which can be reprogrammed into mESCs using induced pluripotency technology. SYBOSS is working with mESCs and focusing on their differentiation into neural (nerve) stem cells (NSCs).
Data hae been gathered for total cellular datasets and gene-specific datasets. Integrated transcriptomic, proteomic and epigenomic analyses of different cell states are now approaching completion.
SYBOSS data will be important for developing standards for cell-based therapies. The broadest socioeconomic impact of the project relates to the development of new ways to treat chronic disabilities in the human population, particularly those related to ageing, as well as genetically based disabilities or degenerative diseases.